CLEC-2-dependent platelet subendothelial accumulation by flow disturbance contributes to atherogenesis in mice

Chaojun Tang1,2,3, Lei Wang1, Yulan Sheng1

  • 1Cyrus Tang Hematology Center, Cyrus Tang Medical Institute, Soochow University, Suzhou, China.

Theranostics
|November 24, 2021
PubMed

Insights

Platelets accumulate in blood vessels under disturbed flow, contributing to vascular inflammation. This process is mediated by platelet CLEC-2 and monocyte PDPN, offering new therapeutic targets for atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Atherosclerosis Research

Background:

  • Platelets are crucial in atherosclerosis development, but mechanisms of their involvement require further elucidation.
  • Disturbed blood flow (d-flow) is a significant factor in initiating vascular inflammation and atherosclerotic plaque formation.

Purpose of the Study:

  • To investigate the role of platelets in d-flow induced vascular inflammation.
  • To elucidate the underlying molecular mechanisms of platelet accumulation in response to d-flow.

Main Methods:

  • Established a d-flow model using partial carotid ligation (PCL) in atherosclerosis-susceptible mice.
  • Utilized immunostaining and transmission electron microscopy to visualize platelet accumulation.
  • Employed gene knockout mice (CLEC-2, PDPN) to explore molecular mechanisms.

Main Results:

  • Observed significant subendothelial accumulation of platelets and monocytes/macrophages in d-flow regions.
  • Deletion of platelet C-type lectin-like receptor 2 (CLEC-2) reduced platelet/monocyte accumulation and ameliorated plaque formation.
  • Myeloid-specific deletion of podoplanin (PDPN), the CLEC-2 ligand, also mitigated d-flow induced accumulation.

Conclusions:

  • Revealed a novel mechanism of CLEC-2-dependent platelet subendothelial accumulation in response to d-flow.
  • This pathway plays a critical role in regulating d-flow induced vascular inflammation and atherosclerosis.
  • The CLEC-2/PDPN axis represents a potential therapeutic target for managing atherosclerosis.